Improving Patient Immuno-Profiling
The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
An area of perhaps even greater attention is immuno-oncology. This is a field that is currently exploding, and the quest to successfully treat and potentially cure cancer is truly the chance of a lifetime. However, many cancer immunotherapies have severe immune-related Adverse Events (irAEs) and are active only in a limited number of patients. Where limited treatment efficacy can be somewhat addressed by the implementation of combination therapies, this only increases the irAE challenge. Therefore, improved patient selection will enable the field of immunotherapy and precision medicine to reach its full potential.
In addition to its partnerships with pharmaceutical and biotechnology companies, Protagen’s strategic collaborations with world-leading institutes such as the National Center for Tumor Diseases (NCT) in Germany, the National Cancer Institute (NCI) in the USA and Gustave Roussy (GR) in France are enabling effective, targeted immunotherapeutic development to improve patient care.
Protagen’s vision of “selecting the right drug for the right patient” is establishing the company as a precision diagnostics leader in the fields of immuno-oncology and autoimmune disease—utilizing the complete value-generation chain from initial discovery through to validation and commercialization for improved patient management.
Download the immuno-oncology eBook to find out more.